An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
For the palliative treatment of patients with advanced prostatic carcinoma.
Benha University, Banhā, Qalyubia, Egypt
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
Diabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
Professor Jacques IRANI, Poitiers, France
Federation d'Endocrinologie, Hopital NeuroCardiologique, Bron, France
Centre MédicoPsychologique CMPG21, EPS Perray Vaucluse, Paris, France
Service de Psychiatrie, Hopital Foch, Suresnes, France
Scarborough General Hospital, Scarborough, England, United Kingdom
Saint Bartholomew's Hospital, London, England, United Kingdom
Barr Laboratories, Incorporated, Pomona, New York, United States
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.